BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -772 Thousand USD | 93.55% |
| 2022 | -11.97 Million USD | 71.55% |
| 2021 | -42.08 Million USD | -37.61% |
| 2020 | -30.58 Million USD | 56.94% |
| 2019 | -71.02 Million USD | -725.49% |
| 2018 | -8.6 Million USD | -23.75% |
| 2017 | -6.95 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -22.81 Million USD | 36.12% |
| 2024 Q1 | -33.99 Million USD | -4302.98% |
| 2023 FY | -772 Thousand USD | 93.55% |
| 2023 Q3 | -6.24 Million USD | 48.46% |
| 2023 Q1 | -10.56 Million USD | 11.74% |
| 2023 Q2 | -12.11 Million USD | -14.6% |
| 2023 Q4 | -772 Thousand USD | 87.63% |
| 2022 Q4 | -11.97 Million USD | 32.39% |
| 2022 FY | -11.97 Million USD | 71.55% |
| 2022 Q3 | -17.71 Million USD | 3.42% |
| 2022 Q2 | -18.33 Million USD | 26.24% |
| 2022 Q1 | -24.86 Million USD | 40.93% |
| 2021 Q1 | -33.91 Million USD | -10.88% |
| 2021 Q4 | -42.08 Million USD | 11.58% |
| 2021 Q3 | -47.59 Million USD | -17.22% |
| 2021 Q2 | -40.6 Million USD | -19.73% |
| 2021 FY | -42.08 Million USD | -37.61% |
| 2020 Q3 | -48.8 Million USD | 16.35% |
| 2020 Q1 | -64.19 Million USD | 11.16% |
| 2020 Q4 | -30.58 Million USD | 37.34% |
| 2020 FY | -30.58 Million USD | 56.94% |
| 2020 Q2 | -58.34 Million USD | 9.11% |
| 2019 Q4 | -72.25 Million USD | -74208.4% |
| 2019 Q3 | -97.23 Thousand USD | 50.6% |
| 2019 Q2 | -196.83 Thousand USD | 38.57% |
| 2019 Q1 | -320.43 Thousand USD | 19.23% |
| 2019 FY | -71.02 Million USD | -725.49% |
| 2018 Q3 | 50.22 Thousand USD | 0.0% |
| 2018 FY | -8.6 Million USD | -23.75% |
| 2018 Q4 | -396.72 Thousand USD | -889.98% |
| 2017 FY | -6.95 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 84.385% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 79.764% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 100.723% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 98.965% |
| Azitra, Inc. | -910.04 Thousand USD | 15.169% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 81.784% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 165.854% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 114.883% |
| CEL-SCI Corporation | 9.42 Million USD | 108.19% |
| iBio, Inc. | -9.75 Million USD | 92.082% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 97.624% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 89.204% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | 39.735% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 276.077% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -97.949% |
| NanoViricides, Inc. | -4.79 Million USD | 83.909% |
| Oragenics, Inc. | -3.17 Million USD | 75.653% |
| BiomX Inc. | -772 Thousand USD | -0.0% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 129.165% |
| Palatin Technologies, Inc. | -8.93 Million USD | 91.362% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 105.571% |